A Part of the University of Maryland Medical Center

Connect with UMGCC

Email page Print page

• Hematologic Malignancies Program

• Diagnosis and Treatment...
• Physicians and Staff
• Q&A with Dr. Maria Baer
• Patient Education...
• 
    Related Resources
• Clinical Trials
• Information for Patients

Hematologic Malignancies Program

 

Vea esta página en español

The Program for Hematologic Malignancies is built on a long-standing tradition of excellence. From its inception as an extramural program of the National Cancer Institute, the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) has been at the forefront of developing and testing new therapies for hematologic malignancies.

As one of the largest experimental therapeutics programs on the East Coast, we offer experimental therapies for all stages of leukemia, lymphoma, Hodgkin's disease and multiple myeloma. Our center is a member of the Myeloproliferative Disorders Research Consortium, an NIH-funded international clinical trials group focusing on myeloproliferative disorders.

Our team of experts includes internationally and nationally recognized leaders in this field, and we continue to set the standard for treating patients with:

• Acute and chronic leukemia
• Lymphomas, including Hodgkin's disease
• Multiple myeloma and other similar disease disorders
• AIDS-related lymphomas

Working with referring physicians to provide patients with the best possible care, we treat all types of hematologic malignancies. Our experts work together throughout the treatment process to ensure that patients receive the highly individualized program of care they need while undergoing complex, aggressive therapies.

• Physicians and Staff
• Diagnostic and Treatment Services
• Patient and Family Education:
  • Cancer Overviews
  • Useful Links

This page was last updated on: December 1, 2011.

Please rate the quality of this article. Do you find this article to be helpful / informative?                Poor                                       Excellent Do you have any brief comments on this page: (up to 255 characters) Note: If you have a question, please contact Ask the Expert.

Email this Page                                                                     Print this Page